Anteris Technologies (AU:AVR) has released an update.
Anteris Technologies Ltd has reported promising outcomes for their DurAVR™ THV valve-in-valve procedures, with Dr. Anita Asgar presenting at New York Valves 2024 that the innovative DurAVR™ valve restored aortic valve gradients to levels comparable to initial post-surgical results in a high-risk patient series. The DurAVR™ THV is a uniquely designed biomimetic aortic replacement valve aimed at addressing the challenges of repeat heart valve replacements, showing no major complications and suggesting improved patient outcomes for future cases.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
